These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 28412474)

  • 1. Kinetics for Drug Discovery: an industry-driven effort to target drug residence time.
    Schuetz DA; de Witte WEA; Wong YC; Knasmueller B; Richter L; Kokh DB; Sadiq SK; Bosma R; Nederpelt I; Heitman LH; Segala E; Amaral M; Guo D; Andres D; Georgi V; Stoddart LA; Hill S; Cooke RM; De Graaf C; Leurs R; Frech M; Wade RC; de Lange ECM; IJzerman AP; Müller-Fahrnow A; Ecker GF
    Drug Discov Today; 2017 Jun; 22(6):896-911. PubMed ID: 28412474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public-Private Partnerships in Lead Discovery: Overview and Case Studies.
    Gottwald M; Becker A; Bahr I; Mueller-Fahrnow A
    Arch Pharm (Weinheim); 2016 Sep; 349(9):692-7. PubMed ID: 27335205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and the drug-target residence time concept.
    Dahl G; Akerud T
    Drug Discov Today; 2013 Aug; 18(15-16):697-707. PubMed ID: 23500610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug target residence time: a misleading concept.
    Folmer RHA
    Drug Discov Today; 2018 Jan; 23(1):12-16. PubMed ID: 28782685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating drug-target association and dissociation mechanisms using metadynamics-based algorithms.
    Cavalli A; Spitaleri A; Saladino G; Gervasio FL
    Acc Chem Res; 2015 Feb; 48(2):277-85. PubMed ID: 25496113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant.
    de Witte WEA; Danhof M; van der Graaf PH; de Lange ECM
    Trends Pharmacol Sci; 2016 Oct; 37(10):831-842. PubMed ID: 27394919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic efficiency: the missing metric for enhancing compound quality?
    Holdgate GA; Gill AL
    Drug Discov Today; 2011 Nov; 16(21-22):910-3. PubMed ID: 21946261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of drug-target residence time.
    Zhang R; Monsma F
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):488-96. PubMed ID: 19562645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive analysis of the influence of drug binding kinetics on drug action at molecular and systems levels.
    Yin N; Pei J; Lai L
    Mol Biosyst; 2013 Jun; 9(6):1381-9. PubMed ID: 23478789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of Drug Binding and Residence Time.
    Bernetti M; Masetti M; Rocchia W; Cavalli A
    Annu Rev Phys Chem; 2019 Jun; 70():143-171. PubMed ID: 30786217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs.
    Zhang R; Monsma F
    Expert Opin Drug Discov; 2010 Nov; 5(11):1023-9. PubMed ID: 22827742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of binding kinetics in therapeutically useful drug action.
    Swinney DC
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):31-9. PubMed ID: 19152211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic binding assays for the analysis of protein-ligand interactions.
    Meyer-Almes FJ
    Drug Discov Today Technol; 2015 Oct; 17():1-8. PubMed ID: 26724330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Target Binding Kinetics in Drug Discovery.
    Guo D; Heitman LH; IJzerman AP
    ChemMedChem; 2015 Nov; 10(11):1793-6. PubMed ID: 26506404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open innovation platforms to boost pharmaceutical collaborations: evaluating external compounds for desired biological activity.
    Nilsson N; Felding J
    Future Med Chem; 2015; 7(14):1853-9. PubMed ID: 26393392
    [No Abstract]   [Full Text] [Related]  

  • 17. Ligand-receptor interaction platforms and their applications for drug discovery.
    Fang Y
    Expert Opin Drug Discov; 2012 Oct; 7(10):969-88. PubMed ID: 22860803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of discovery DMPK scientists in industry: where do we go from here?
    Moriwaki T
    Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22666880
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of discovery DMPK scientists in industry: where do we go from here?
    Moriwaki T
    Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22531680
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients.
    de Witte WE; Wong YC; Nederpelt I; Heitman LH; Danhof M; van der Graaf PH; Gilissen RA; de Lange EC
    Expert Opin Drug Discov; 2016; 11(1):45-63. PubMed ID: 26484747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.